import
secondgener
case
manifest
less
complic
lower
fatal
higher
discharg
rate
initi
case
may
relat
shorter
interv
symptom
onset
hospit
admiss
younger
age
higher
lymphocyt
count
import
secondgener
patient
lymphocyt
count
level
could
use
indic
evalu
prognosi
pulmonari
fibrosi
found
later
chest
ct
imag
half
pneumonia
case
taken
account
mortal
differ
countri
region
report
larg
focus
firstgener
case
studi
aim
clarifi
clinic
characterist
import
secondgener
case
retrospect
multicent
cohort
studi
includ
confirm
case
citi
outsid
wuhan
epidemiolog
clinic
outcom
data
extract
medic
record
compar
sever
nonsever
case
profil
dynam
laboratori
find
patient
patient
sever
case
complic
march
patient
discharg
one
patient
die
median
age
year
median
interv
symptom
onset
hospit
admiss
iqr
day
median
lymphocyt
count
l
age
lymphocyt
count
crp
esr
dbil
ldh
hbdh
show
differ
sever
nosever
case
p
baselin
lymphocyt
count
higher
surviv
patient
nonsurvivor
case
increas
condit
improv
declin
sharpli
death
occur
level
display
downtrend
survivor
rose
high
death
case
pulmonari
fibrosi
found
later
chest
ct
imag
pneumonia
case
import
secondgener
case
outsid
wuhan
better
prognosi
initi
case
right
reserv
reus
allow
without
permiss
decemb
cluster
pneumonia
case
unknown
caus
occur
citi
wuhan
china
earli
januari
novel
betacoronaviru
isol
bronchoalveolar
lavag
sampl
infect
patient
pathogen
name
sever
acut
respiratori
syndrom
coronaviru
previous
known
novel
coronaviru
februari
offici
design
syndrom
coronaviru
diseas
due
humantohuman
transmiss
spread
rapidli
march
total
case
confirm
china
case
report
countri
contin
clinic
spectrum
appear
wide
includ
asymptomat
infect
mild
respiratori
tract
ill
sever
pneumonia
respiratori
failur
even
death
mortal
differ
among
countri
region
instanc
china
vietnam
itali
austrilia
far
studi
epidem
clinic
characterist
mainli
concentr
initi
firstgener
case
inform
import
secondgener
case
limit
studi
focus
shaanxi
provinc
region
import
secondgener
case
describ
clinic
laboratori
characterist
case
provinc
hope
provid
insight
prevent
treatment
diseas
china
elsewher
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
retrospect
studi
includ
confirm
case
admit
treat
design
hospit
across
citi
xian
ankang
baoji
hanzhong
weinan
xianyang
shangluo
yanan
tongchuan
shaanxi
provinc
januari
march
supplementari
materi
infect
defin
accord
version
guidelin
issu
nation
health
commiss
peopl
republ
china
epidemiolog
demograph
clinic
laboratori
radiolog
characterist
well
treatment
outcom
data
collect
patient
electron
medic
record
use
standardis
case
report
form
clinic
outcom
follow
march
data
review
train
team
physician
inform
clear
research
team
contact
doctor
respons
treat
patient
clarif
urgent
need
collect
data
regard
emerg
pathogen
requir
inform
consent
waiv
laboratori
confirm
perform
immedi
admiss
verifi
shaanxi
provinci
center
diseas
control
prevent
cdc
confirm
case
defin
posit
result
highthroughput
sequenc
realtim
reversetranscriptas
polymeras
chain
reaction
rtpcr
assay
nasal
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
pharyng
swab
sampl
sputum
specimen
date
diseas
onset
defin
day
symptom
notic
fever
defin
axillari
temperatur
ard
defin
accord
berlin
definit
acut
kidney
injuri
identifi
base
kidney
diseas
improv
global
outcom
definit
cardiac
injuri
determin
serum
level
cardiac
biomark
eg
troponin
percentil
upper
refer
limit
new
abnorm
detect
electrocardiographi
echocardiographi
ventilatorassoci
pneumonia
determin
refer
guidelin
treatment
hospitalacquir
ventilatorassoci
pneumonia
sever
categor
nonsever
group
mild
moder
sever
group
sever
critic
ill
base
version
guidelin
issu
nation
health
commiss
peopl
republ
china
cohort
patient
divid
sever
nonsever
case
continu
categor
variabl
express
median
iqr
n
respect
mannwhitney
test
use
continu
variabl
test
fisher
exact
test
data
limit
use
categor
variabl
compar
differ
sever
nonsever
case
appropri
statist
analys
perform
spss
softwar
version
twosid
less
consid
statist
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
signific
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
studi
recruit
total
patient
citi
shaanxi
provinc
confirm
infect
januari
march
median
age
patient
year
old
iqr
rang
year
half
femal
tabl
altogeth
case
nonsever
sever
includ
two
critic
ill
case
one
patient
unabl
surviv
tabl
age
sever
patient
significantli
older
nonsever
patient
median
year
vs
year
p
moreov
proport
patient
age
older
higher
vs
p
proport
patient
age
lower
vs
p
group
sever
patient
nonsever
patient
tabl
none
patient
histori
exposur
huanan
seafood
market
wild
anim
major
case
communityinfect
three
case
hospitalinfect
patient
resid
wuhan
short
trip
wuhan
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
patient
one
coexist
medic
condit
common
hypertens
follow
diabet
cardiovascular
diseas
cerebrovascular
diseas
tabl
common
symptom
onset
cough
follow
fever
tabl
incid
chest
stuffi
dyspnea
differ
sever
nosever
case
tabl
p
median
interv
onset
symptom
first
hospit
admiss
iqr
day
posit
result
nucleic
acid
detect
iqr
day
median
durat
hospit
admiss
discharg
day
iqr
tabl
upon
admiss
measur
vital
sign
record
patient
incid
temperatur
respiratori
rate
breath
per
minut
heart
rate
beat
per
minut
median
systol
pressur
show
differ
sever
nosever
case
tabl
p
higher
sever
case
compar
nonsever
case
patient
show
abnorm
chest
ct
imag
consist
case
unilater
pneumonia
case
bilater
pneumonia
groundglass
opac
typic
hallmark
find
among
patient
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
case
progress
white
lung
addit
pleural
effus
occur
patient
pneumothorax
occur
patient
shadow
consolid
resolv
fibrou
stripe
pulmonari
fibrosi
found
later
chest
ct
imag
patient
tabl
moreov
incid
bilater
pneumonia
pleural
effus
pulmonari
fibrosi
higher
sever
case
nonsever
case
tabl
p
tabl
number
laboratori
paramet
show
higher
valu
sever
patient
compar
nonsever
patient
tabl
includ
creactiv
protein
crp
erythrocyt
sediment
rate
esr
direct
bilirubin
dbil
glucos
lactat
dehydrogenas
ldh
hydroxybutyr
dehydrogenas
hbdh
probrain
natriuret
peptid
tabl
p
addit
lymphocyt
count
albumin
compar
lower
sever
patient
nonsever
patient
tabl
p
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
hospit
patient
complic
includ
arrhythmia
acut
respiratori
distress
syndrom
acut
kidney
injuri
ventilatorassoci
pneumonia
multipl
organ
dysfunct
syndrom
shock
complic
occur
group
sever
case
incid
complic
compar
higher
sever
case
nonsever
case
vs
p
tabl
therapeut
manag
patient
receiv
oxygen
inhal
two
critic
ill
case
treat
noninvas
ventil
niv
one
switch
invas
mechan
ventil
imv
extracorpor
membran
oxygen
ecmo
continu
renal
replac
therapi
crrt
salvag
therapi
die
switch
invas
mechan
ventil
tabl
patient
experienc
secondari
bacteria
infect
detect
posit
secondari
fungu
infect
virus
infect
tabl
empir
singl
antibiot
treatment
mainli
moxifloxacin
given
patient
median
durat
day
iqr
patient
receiv
antivir
therapi
median
durat
day
iqr
includ
lopinavirritonavir
interferon
alpha
inhal
arbidol
ribaviron
chloroquin
median
interv
onset
symptom
antivir
therapi
iqr
day
tabl
addit
patient
receiv
antifung
treatment
tabl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
glucocorticoid
therapi
median
durat
day
iqr
perform
patient
durat
remark
longer
sever
case
nonsever
case
median
vs
p
median
interv
onset
symptom
glucocorticoid
therapi
day
iqr
addit
case
support
gamma
globulin
median
day
iqr
significantli
sever
case
given
oxygen
inhal
antibiot
systemat
corticosteroid
gamma
globulin
p
tabl
march
patient
discharg
one
critic
patient
die
remain
patient
still
treatment
larg
sever
case
sever
vs
nonsever
p
tabl
fit
discharg
base
abat
fever
least
three
day
significantli
improv
respiratori
symptom
neg
result
two
consecut
respiratori
pathogen
nucleic
acid
test
sampl
interv
least
day
determin
major
clinic
featur
progress
dynam
chang
six
clinic
laboratori
paramet
name
lymphocyt
crp
ldh
hbdh
dbil
monitor
everi
day
day
day
hospit
admiss
januari
data
complet
clinic
cours
seven
patient
includ
five
randomli
select
discharg
patient
critic
case
manag
ecmo
nonsurvivor
case
analyz
figur
baselin
lymphocyt
count
significantli
higher
survivor
nonsurvivor
patient
survivor
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
lymphocyt
count
lowest
day
admiss
increas
gradual
hospit
wherea
nonsurvivor
patient
develop
sever
lymphopenia
l
time
level
survivor
display
gradual
decreas
normal
rang
condit
improv
increas
unexpectedli
high
valu
death
nonsurvivor
case
compar
recov
patient
level
crp
ldh
hbdh
dbil
two
critic
ill
patient
higher
throughout
clinic
cours
figur
recov
level
four
marker
reach
peak
day
admiss
decreas
subsequ
recoveri
two
critic
ill
case
level
increas
rapidli
day
condit
deterior
patient
enrol
multicent
studi
expos
huanan
seafood
market
wild
anim
major
patient
clear
histori
wuhan
close
contact
individu
wuhan
patient
larg
number
famili
cluster
data
provid
evid
strong
abil
humantohuman
transmiss
besid
fact
patient
definit
epidemiolog
histori
might
suggest
possibl
transmiss
asymptomat
individu
present
confirm
patient
main
sourc
infect
deserv
particular
attent
asymptomat
transmiss
could
anoth
sourc
infect
moreov
patient
histroy
exposur
wuhan
never
wuhan
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
percentag
male
patient
data
differ
male
patient
predomin
report
two
studi
wuhan
case
huang
et
al
chen
et
al
studi
malefemal
ratio
approxim
differ
sever
nonsever
case
find
contradict
previou
conclus
men
suscept
women
might
relat
occup
exposur
men
women
work
salesmen
market
manag
seafood
market
record
patient
huang
report
patient
chen
report
histori
exposur
huanan
seafood
market
affect
patient
male
worker
contrast
patient
studi
exposur
indic
chang
transmiss
mode
outsid
wuhan
gender
may
suscept
factor
similarli
sever
patient
much
older
nonsever
patient
suggest
age
may
import
risk
factor
poor
outcom
role
age
seem
similar
role
sar
mer
report
independ
predictor
advers
outcom
tcell
bcell
hypofunct
excess
product
type
cytokin
older
peopl
could
lead
defect
inhibit
viral
replic
stronger
host
innat
respons
sustain
cytokin
storm
potenti
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
lead
poor
outcom
therefor
compromis
immun
function
might
major
caus
higher
mortal
older
peopl
infect
coronavirus
proport
sever
case
shaanxi
close
wuhan
report
wang
et
al
incid
complic
mortal
consider
lower
among
shaanxi
patient
among
initi
infect
wuhan
patient
two
case
cohort
need
mechan
ventil
might
indic
patient
outsid
wuhan
much
better
prognosi
first
gener
patient
wuhan
case
wuhan
initi
identifi
higher
mortail
confirm
treat
later
vs
vs
phenomenon
similar
transmiss
merscov
global
mortal
firstgener
merscov
secondgener
around
furthermor
median
interv
symptom
onset
hospit
admiss
shaanxi
case
shorter
wuhan
case
vs
day
shaanxi
patient
younger
wuhan
vs
year
may
reason
notabl
reduct
mortal
shaanxi
case
percentag
case
fever
cohort
lower
report
wuhan
regard
patient
normal
temperatur
may
miss
surveil
case
definit
focus
heavili
fever
detect
compar
nonsever
patient
sever
patient
commonli
symptom
sign
cough
sputum
chest
stuffi
dyspnea
temperatur
respiratori
rate
breath
per
minut
heart
rate
beat
per
minut
onset
symptom
sign
may
assist
physician
identifi
patient
greater
sever
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
base
radiolog
data
incid
bilater
pneumonia
pleural
effus
higher
sever
case
nonsever
case
suggest
greater
diseas
sever
similar
report
sun
et
al
pneumonia
case
pulmonari
fibrosi
found
later
chest
ct
imag
shadow
resolv
phenomenon
common
sever
patient
nonsever
patient
find
consist
suggest
pulmonari
fibrosi
one
sequela
necessari
import
explor
prevent
reduc
occurr
pulmonari
fibrosi
manag
situat
whenev
occur
treatment
term
laboratori
test
differ
case
wuhan
shaanxi
patient
lymphocyt
within
normal
rang
show
lymphopenia
lymphocyt
absolut
count
cohort
patient
l
higher
report
wuhan
patient
l
may
anoth
reason
lower
mortal
shaanxi
case
compar
wuhan
case
sever
case
lymphocyt
count
lower
incid
lymphopenia
higher
find
suggest
might
mainli
act
lymphocyt
especi
lymphocyt
sever
lymphopenia
might
reflect
sever
diseas
furthermor
level
inflammatoryparamet
crp
esr
elev
patient
even
higher
sever
patient
chang
laboratori
paramet
illustr
viru
invad
respiratori
mucosa
spread
bodi
trigger
seri
immun
respons
induc
sever
inflamm
cytokin
storm
vivo
patient
studi
abnorm
level
alanin
aminotransferas
alt
aspart
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
aminotransferas
ast
indirect
bilirubin
idbil
median
level
dbil
patient
elev
even
higher
sever
patient
report
potenti
mechan
liver
dysfunct
could
viru
might
directli
bind
posit
bile
duct
cell
therefor
liver
abnorm
patient
may
caus
liver
cell
damag
bile
duct
cell
dysfunct
addit
elev
glucos
ldh
hbdh
probrain
natriuret
peptid
well
declin
albumin
commonli
seen
sever
case
suggest
greater
diseas
sever
dynam
chang
six
laboratori
marker
show
baselin
lymphocyt
count
significantli
higher
survivor
nonsurvivor
patient
lymphocyt
count
show
gradual
increas
condit
improv
declin
sharpli
death
occur
convers
level
display
downtrend
survivor
continu
rose
high
level
nonsurvivor
patient
henc
assum
cellular
immun
function
might
relat
mortal
lymphocyt
use
indic
prognosi
addit
crp
ldh
hbdh
dbil
level
decreas
condit
improv
recov
patient
increas
rapidli
condit
worsen
nonsurvivor
patient
critic
case
may
relat
cytokin
storm
bile
duct
cell
dysfunct
induc
viru
invas
patient
studi
receiv
antivir
therapi
includ
lopinavirritonavir
interferon
alpha
inhal
arbidol
ribaviron
chloroquin
specif
treatment
recommend
infect
except
optim
support
care
previou
studi
show
combin
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
lopinavir
ritonavir
associ
substanti
clinic
benefit
sar
infect
anoth
studi
claim
remdesivir
good
therapeut
effect
current
randomis
clinic
trial
lopinavirritonavir
intraven
remdesivir
treatment
progress
meanwhil
vaccin
highli
expect
ongo
effort
need
explor
effect
therapi
emerg
acut
respiratori
infect
studi
limit
first
covid
patient
shaanxi
recruit
conclus
need
verifi
recruit
larger
number
case
provinc
citi
outsid
wuhan
second
critic
ill
case
nonsurvivor
studi
thu
dynam
observ
laboratori
paramet
nonsurvivor
survivor
recov
case
critic
ill
case
descript
analysi
larger
number
critic
ill
case
need
verifi
observ
summari
present
studi
identifi
import
secondgener
case
shaanxi
better
prognosi
compar
initi
firstgener
case
wuhan
less
complic
lower
fatal
higher
discharg
rate
differ
may
relat
shorter
interv
symptom
onset
hospit
admiss
younger
age
higher
lymphocyt
count
patient
shaanxi
lymphocyt
count
level
could
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
use
indic
evalu
prognosi
crp
ldh
hbdh
dbil
level
could
help
estim
sever
develop
tendenc
diseas
pulmonari
fibrosi
found
later
chest
ct
imag
half
pneumonia
case
taken
account
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
author
declar
compet
interest
studi
approv
ethic
committe
first
affili
hospit
xian
jiaotong
univers
grate
healthcar
worker
involv
diagnosi
treatment
covid
patient
thank
colleagu
help
us
current
studi
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
p
valu
indic
differ
sever
nonsever
patient
p
consid
statist
signific
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
white
blood
cell
count
l
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
p
valu
indic
differ
sever
nonsever
patient
p
consid
statist
signific
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
p
valu
indic
differ
sever
nonsever
patient
p
consid
statist
signific
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
